Analyzing Daxor (NASDAQ:DXR) and Integra LifeSciences (NASDAQ:IART)

Daxor (NASDAQ:DXR) and Integra LifeSciences (NASDAQ:IART) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Daxor and Integra LifeSciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$2.13 million	17.77	N/A	N/A	N/A
Integra LifeSciences	$1.61 billion	0.81	$67.74 million	($0.09)	-186.78

Integra LifeSciences has higher revenue and earnings than Daxor.

Volatility & Risk

Daxor has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Profitability

This table compares Daxor and Integra LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Integra LifeSciences	-0.42%	12.35%	4.82%

Institutional & Insider Ownership

1.3% of Daxor shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 59.0% of Daxor shares are owned by insiders. Comparatively, 3.5% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Daxor and Integra LifeSciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	1	0	3.00
Integra LifeSciences	3	4	2	0	1.89

Daxor currently has a consensus target price of $25.00, suggesting a potential upside of 219.28%. Integra LifeSciences has a consensus target price of $22.71, suggesting a potential upside of 35.12%. Given Daxor’s stronger consensus rating and higher possible upside, research analysts clearly believe Daxor is more favorable than Integra LifeSciences.

Summary

Integra LifeSciences beats Daxor on 6 of the 11 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.